A recent executive order directing federal agencies to accelerate research pathways for psychedelic drugs named only one compound specifically by name: ibogaine. The announcement was framed as the opening of a new frontier. But ibogaine is neither new nor uncharted.

It is a naturally occurring indole alkaloid that was first marketed in France as a neuromuscular stimulant for fatigue and depression nearly 90 years ago. More recently, preliminary studies have suggested ibogaine’s potential for the treatment of opioid dependence, posttraumatic stress disorder (PTSD), traumatic brain injury (TBI), depression, and substance use disorder (SUD).

Despite that long history, there have been no randomized, placebo-controlled trials for ibogaine, its mechanism of action remains poorly understood, and it carries a documented cardiac risk that has caused fatal arrhythmias outside monitored settings.

The directive signed by President Donald Trump on April 18 seeks to speed the development of psychedelic-based therapeutics, allocates $50 million for federal-state research partnerships, and directs the FDA to establish a Right to Try pathway for psychedelics, including ibogaine compounds.

As interest in the ibogaine grows, clinicians are looking for information to help them parse the excitement from the evidence.

What Is Ibogaine?

Ibogaine is derived from the root bark of Tabernanthe iboga, a shrub native to West Central Africa, where it has been used in tribal rituals for thousands of years. The compound produces a vivid, dream-like state that typically begins within a few hours of ingestion and can last 24 hours or more. In the US, ibogaine is a Schedule I controlled substance, and its use outside of approved research settings is illegal.

Ibogaine interacts with neurotransmitters in the central nervous system. The compound’s neuronal receptor targets — such as serotonin, dopamine, glutamate, and opioid receptors — have been extensively catalogued, but which specific interaction produces therapeutic effects remains unknown.

“We don’t know how it works, and that is what is so interesting about it,” Kenneth Alper, MD, a clinical psychopharmacologist and visiting scientist at the Nathan Kline Institute for Psychiatric Research in Orangeburg, New York, told Medscape Medical News.

After ingestion, ibogaine rapidly converts to noribogaine, a metabolite discovered in the 1990s by researchers Deborah C. Mash, PhD, a neuropharmacologist and now a professor emeritus of neurology and molecular and cellular pharmacology at the University of Miami in Miami, and Juan Sanchez-Ramos, MD, PhD, now a professor emeritus of neurology at the University of South Florida in Tampa, Florida.

The pair received an investigational new drug license in 1993 for phase 1 human safety trials for drug addiction — the first FDA authorization for ibogaine research in humans — but the study was halted in 1995 when their funding from the National Institute on Drug Abuse (NIDA) ran out. Mash later founded the company DemeRx to further the development of noribogaine.

Noribogaine has a half-life of 20-27 hours and sustains activity across serotonin, opioid, and neuroplasticity-related signaling systems.

“When it converts to noribogaine, the visions abruptly cease, and patients go into deep cognitive introspection,” Mash told Medscape Medical News.

What Does the Evidence Show?

In the absence of any randomized controlled trials, the evidence base for ibogaine relies mostly on case series and open-label studies.

The largest published ibogaine dataset comes from Healing Visions, a fee-for-service detoxification clinic that Mash operated in St. Kitts from 1996 to 2005 for treatment-refractory patients with SUD who had not responded to standard care. Mash moved the work offshore after the NIDA grant ended. The program operated with University of Miami and St. Kitts government approval but not under FDA oversight.

The data, first reported in a 27-patient prospective study in 2000 and consolidated in a 2018 review, span 191 patients with opioid and cocaine addiction who each received a single oral dose of 10-12 mg/kg of ibogaine. Physician-rated opioid withdrawal scores dropped to near zero within hours of dosing, mean depression scores fell from above the clinical threshold at baseline to minimal symptoms at 1 month, and heroin craving decreased significantly, with reductions sustained at 1-month follow-up.

Patients dependent on cocaine showed comparable reductions in craving and a more rapid improvement in depressive symptoms. Additionally, only 16.7% of patients said they would repeat the ibogaine experience, suggesting low abuse liability.

Ibogaine-treated patients in that cohort were less likely to anticipate positive outcomes from drug use and more likely to believe in their control over abstaining, a pattern that Mash’s group framed as evidence of cognitive change beyond simple withdrawal relief.

“It completely blocked the signs and symptoms of opioid withdrawal,” Mash said, “but not only that, patients were thinking straight. They weren’t craving to go out and get high again.”

Evidence is more preliminary for TBI and PTSD, two indications driving the current political momentum. Most data come from the MISTIC study, an open-label investigation designed and led by the late Nolan Williams, MD, who was a professor of psychiatry and behavioral sciences and director of the Stanford Brain Stimulation Lab.

In this study, reported by Medscape Medical News in 2024, 30 male Special Operations Forces veterans received a single oral dose of ibogaine (averaging 12 mg/kg) with intravenous magnesium at a clinic in Mexico. At 1 month, PTSD symptoms decreased 88%, depression 87%, and anxiety 81%, with effect sizes above 2.0 and remission rates of 83%-86%. Disability and cognitive scores also improved significantly.

There is no FDA-approved treatment for chronic post-TBI symptoms, which makes any positive signal noteworthy, said co-investigator Ian Kratter, MD, PhD, clinical assistant professor of psychiatry and behavioral science at Stanford Medicine in Stanford, California.

“If the signal we found were to be replicated, that would be very exciting for potentially a lot of people who’ve had significant concussions or mild brain injuries,” Kratter told Medscape Medical News.

But as with other ibogaine studies, there were significant limitations in the MISTIC trial: no placebo control, no blinding, a small homogeneous cohort, treatment at an unregulated clinic in Mexico without the investigators present during dosing, and ibogaine delivered alongside magnesium.

Is Ibogaine Safe?

Ibogaine use is linked to a number of safety concerns. The most serious of these is QT prolongation caused by the drug’s inhibition of the hERG potassium channel, which can lead to fatal cardiac arrhythmias.

A 2012 review led by Alper detailed 19 fatalities that occurred following ibogaine ingestion between 1990 and 2008, with subsequent updates bringing the total to 33. The causal role of ibogaine could not always be established and the deaths occurred predominantly in unregulated treatment settings, such as underground ceremonies, off-label clinics, and self-administration. The review showed that fatalities were clustered around preexisting cardiovascular disease, concurrent use of other central nervous system depressants such as opioids and benzodiazepines, and absent or inadequate pretreatment cardiac screening.

The cardiac risk is the development bottleneck. “It’s the kiss of death for most drugs in any pipeline,” David Olson, PhD, professor of biochemistry and molecular medicine at University of California, Davis, told Medscape Medical News. In 2020, Olson’s lab developed a non-hallucinogenic, non-cardiogenic synthetic ibogaine analogue designed to address those cardiac concerns.

In monitored settings, the cardiac risk has been manageable. Across Mash’s 191-patient St. Kitts cohort — all on continuous ECG telemetry with CYP2D6 genotyping — transient QT prolongation returned to baseline with no clinically significant arrhythmias, hospitalizations, or deaths.

The magnesium coadministration protocol Mash developed after observing bradyarrhythmia in volume-depleted patients — combined with prescreening, 24-hour telemetry, and a strict single-dose rule — became the framework MISTIC later adopted. MISTIC similarly reported no serious cardiac adverse events.

However, in January 2026, a patient died during treatment at the Ambio Life Sciences clinic in Mexico, the same facility where MISTIC participants were treated, though the patient was involved in a separate detoxification program for patients with SUDs. Ambio cited the increasing complexity of street fentanyl adulterants as an escalating risk factor and announced enhanced screening protocols in response.

What Is the Status of Drug Development?

Less than a week after the executive order was signed, the company Mash founded, DemeRx, announced FDA acceptance of an investigational new drug application for DMX-001 (oral noribogaine), an experimental treatment for alcohol use disorder (AUD). The FDA also authorized a phase 1 trial of the drug, the first time the agency has allowed a US-based clinical trial of an ibogaine derivative. Details are not yet available. Meanwhile, following positive results from an earlier dosing study in healthy volunteers in London, the company has also announced plans for a 2027 phase 2 trial of DMX-001 in individuals with AUD.

Delix Therapeutics, co-founded by Olson, is developing a non-hallucinogenic ibogaine analogue called DLX-007, a potential first-in-class drug for SUD that is designed to retain neuroplasticity while eliminating cardiotoxicity. The company, which received a NIDA grant in 2023 to fund the work, is also investigating DLX-007 for major depressive disorder.

Gilgamesh Pharmaceuticals is developing another cardiac-safe ibogaine analogue, GM-3009, for the treatment of opioid use disorder. Support from a NIDA grant will enable the launch of a phase 1 clinical trial later this year, the company reports.

All three drugs aim to capture ibogaine’s therapeutic potential without its psychedelic effects or cardiac side effects. “Do you need the trip to reach the destination? There are people on both sides of the aisle on this,” said Mash.

Soneira Bio, where Kratter serves as chief medical officer, is developing SON-001, a patent-pending formulation of ibogaine with a cardiac-protective agent based on work completed at Stanford by Williams and Kratter. The compound is being developed for TBI-associated disabilities, including depression and anxiety. While the drug is designed to avoid cardiac side effects, unlike other investigational ibogaine compounds, SON-001 will retain its hallucinogenic properties. 

Kratter said the practical impact for ibogaine will depend on what comes next. “What we really need is a double-blind, randomized, controlled trial done under very rigorous conditions.”

What Should Clinicians Tell Patients?

According to Mash and Kratter, patients with depression, PTSD, TBI, and SUD who have exhausted conventional treatments are increasingly seeking out ibogaine on their own. In what Mash called “a vast underground ibogaine experiment,” patients are traveling to clinics that operate outside the FDA framework, with widely varying standards for cardiac screening and dose protocols.

Mash warned that patients seeking treatment in those settings face risks beyond inadequate cardiac monitoring.

Individuals seeking treatment in unregulated clinics “need to understand that they’re not being treated with ibogaine with a package insert. There’s no label here. And they don’t even know the purity of the product they’re being given,” she said.

If a patient raises the topic, Kratter said clinicians could suggest they find a US clinical trial that is accepting patients. Given the increased federal attention on ibogaine, those choices could increase as more companies seek to develop ibogaine-derived therapeutics.

For now, the study of ibogaine remains where it has been for three decades — showing real signals in observational data, carrying real cardiac risk, and awaiting the controlled trials clinicians say they need to guide patient care.

Mash reported being the CEO and founder of DemeRx. Additional disclosure information for Mash and the MISTIC study authors is available in the original publications cited in this article. Olson reported serving as the chief innovation officer of Delix Therapeutics. Alper reported having no relevant financial relationships. Kratter reported being a named inventor on Stanford-owned intellectual property (IP) relating to magnesium-ibogaine coadministration.